

SEARCH REQUEST FORM

64839

Requestor's Name: BERTH

Serial Number: 589858


Date: 4/8/02

Phone: 4718

Art Unit: 1624

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).



RECEIVED

3-2-02

(STIC)

chain only

MAR 2


851-56

bech 889858

and 1/23/02, are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to helpcas.org for further assistance or to receive a credit for any duplicate searches.

=> str

=> d 13 que stat;d 1-179 ide cbib abs



STR

VPA 11-7/9 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L3 179 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 2172 ITERATIONS
SEARCH TIME: 00.00.01
179 ANSWERS

L3 ANSWER 1 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347161-70-0 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[3-(1-piperidinyl)propyl] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H30 N6 O6
SR CA
LC STN Files: CA, CAPLUS


Searched by: Mary Hale 308-4258 CM-1 12D16

GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakajishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, 3-BrC6H4CONHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II



I

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 2 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347161-69-7 REGISTRY

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[4-(1-piperidinyl)butyl] - (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C26 H32 N6 O6

SR CA

LC STN Files: CA, CAPLUS

II




GI

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I







L3 ANSWER 3 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-46-1 REGISTRY
 CN Urea, N-[2-(dibutylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H39 N5 O5
 SR CA
 LC STN Files: CA, CAPLUS

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I




2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Tetsuyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW. AM, AZ, BY, BG, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI

I




II



AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, 4-ClC6H4(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as infimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinazoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

G1



AB Title comps. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2OCONH, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 4 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-45-0 REGISTRY
 CN Urea, N-[2-(dibutylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H36 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS


Searched by: Mary Hale 308-4258 CM-1 12D16

GI

REFERENCE 1: 135:92649 Preparation of quinaoline and quinoiline derivatives
as remedies for diseases mediated by autophosphorylation of PDGF
receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa,
Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890
A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, BG, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2.
APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;
JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



19


ENCE 2: 135:76901 Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

Title comps. [I; X = N, CH; R³, R⁴, R⁵, R⁶ independently = H, Cl, F, CH₃, CH₃O, NO₂; A = 4-CH₃CH₆CH₂CO₂CH₃, 3-ClCH₆CH₄CH₃OCO₂CH₃, 4-FC₆H₄CH₂CO₂CH₃, 2-ClC₆H₄CH₂CH₂CO₂CH₃, 4-FC₃CH₆CH₄CH₂CO₂CH₃, CH₃(CH₂)₅OCO₂CH₃, (CH₃CH₂)₂N(CH₂)₃NHCSNH, YNHCONH, 4-ClC₆H₄O(CH₂)₂S, 4-ClC₆H₄(CH₂)₂NH, 3-BrC₆H₄CONHCSNH, C₆H₅COO, OH, OCH₂COOCH₃, OCH₂COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed compd. II was prepd. and bptl. tested.



II


I



L3 ANSWER 5 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-44-9 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(dibutylamino)ethyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H36 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2CH2OCOH, 4-FC6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCOH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.


II




2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinaldine and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI



I




II

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2OCOH, 4-ClC6H4(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.


REFERENCE 2: 135:76901 Preparation of quinazoline and quinazoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

G1



AB Title comps. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH2OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prep. and biol. tested.

L3 ANSWER 6 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-43-8 REGISTRY
 CN Urea, N-[2-(dibutylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H37 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI

19


ENCE 2: 135:76901. Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakasahi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

little comps. [1; x = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2COCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2COCONH, 4-FC6H4CH2COCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; X = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclialkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 7 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347156-38-1 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[2-(1-piperidinyl)ethyl] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H31 N5 O5
SR CA
LC STN Files: CA, CAPLUS




II

GI


REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT





PAGE 2-A



PAGE 1-A


II



AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 8 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-37-0 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-piperidinyl)ethyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H28 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Terunumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3C6H4OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4OCONH, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2CH2OC(=O)NH, 4-ClC6H4CH2OC(=O)NH, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CF3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2CH2OC(=O)NH, 4-ClC6H4CH2OC(=O)NH, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 9 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347156-36-9 REGISTRY

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-piperidinyl)ethyl] - (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C24 H29 N5 O4

SR CA

LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, TR, TT, TZ, UA, UG, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II

I

AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2CH2OC(=O)NH, 4-ClC6H4CH2OC(=O)NH, 2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CF3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 10 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347156-28-9 REGISTRY

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-(2-ethyl[3-methylphenyl]amino)ethyl] - (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C29 H33 N5 O5

SR CA

LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI

REFERENCE 2: 135:76901 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prep. and biol. tested.





AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 11 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347156-27-8 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-[ethyl(3-methylphenyl)amino]ethyl] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H30 N6 O6
SR CA
LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinaline derivatives
as remedies for diseases mediated by autophosphorylation of PDGF
receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa,
Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890
A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, BG, GR, GA, GB, GR, IE, IT, LU, MC,
CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2.
APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;
JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

Searched by: Mary Hale 308-4258 CM-1 12D16


GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II






I

AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COONH, 3-ClC6H4CH(CH3)COONH, 4-FC6H4CH2COONH, 2-ClC6H4CH(CH3)COONH, 2-ClC6H4CH2CH2COONH, 4-CF3C6H4CH2COONH, CH3(CH2)5COONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 12 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-25-6 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-[ethyl(3-methylphenyl)amino]ethyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H30 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinaldine derivatives
as remedies for diseases mediated by autophosphorylation of PDGF
receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa,
Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890
A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, BG, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2.
APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;
JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanisshi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and mediated by autophosphorylation of PDGF receptors, particularly useful as prepd. and biol. tested. Thus, the title claimed compd. II was

II




I





AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2CH2OCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CFC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4OCH2COOCH3, OCH2COOCH3; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 13 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347156-24-5 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-[ethyl(3-methylphenyl)amino]ethyl]]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H31 N5 O4
SR CA
LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16

GI


REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOH, Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prep. and biol. tested.

II




I





L3 ANSWER 14 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-20-1 REGISTRY
 CN Urea, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H35 N5 O5
 SR CA
 LC STN Files: CA, CAPLUS

AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH2OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH2OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCOH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.




II

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Tetsuyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI

I




II



AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, 4-ClC6H4(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as infimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinaldine and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI




AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 15 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347156-19-8 REGISTRY
CN Urea, N-[2-[bis[1-methylethyl]amino]ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]]-(9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C25 H32 N6 O6
SR CA
LC STN Files: CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I






L3 ANSWER 16 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-17-6 REGISTRY
 CN Urea, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-(2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl)] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H32 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI



I



II

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COONH, 3-ClC6H4CH(CH3)OCOONH, 4-FC6H4CH2COONH, 2-ClC6H4CH(CH3)OCOONH, 2-ClC6H4CH2CH2COONH, 4-FC6H4CH2COONH, CH3(CH2)5COONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2COONH, 4-ClC6H4(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intraluminal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

19



AB

LC
SR
MF
FS
CN
RN
L3

Searched by: Mary Hale 308-4258 CM-1 12D16


GI

REFERENCE 1: 135:92649 Preparation of quinaoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BY, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




GI


REFERENCE 2: 135:76901 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BY, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I



AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 18 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347156-13-2 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-(1-pyrrolidinyl)ethyl] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H26 N6 O6
SR CA
LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinoaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I



AB Title compds. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 19 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-12-1 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-(4-morpholinyl)ethyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H26 N6 O7
 SR CA
 LC STN Files: CA, CAPLUS

II




GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


19


REFERENCE 2: 135:76901 Preparation of guinazoline and guinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCNH, 3-ClC6H4CH(CH3)OCNH, 4-FC6H4CH2OCNH, 2-ClC6H4CH(CH3)OCNH, 2-ClC6H4CH2CH2OCNH, 4-FC6H4CH2OCNH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclicalkyl] and pharmaceutically acceptable salts are prep'd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimate thickening inhibitors. Thus, the title claimed comp'd. II was prep'd. and biol. tested.



I






LC STN Files: CA, CAPLUS
 SR CA
 MF C23 H28 Cl N5 O4
 FS 3D CONCORD
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(diethylamino)ethyl] - (9CI) (CA INDEX NAME)
 RN 347156-06-3 REGISTRY
 L3 ANSWER 20 OF 179 REGISTRY COPYRIGHT 2002 ACS

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2CO2NH, 3-ClC6H4CH(CH3)CO2NH, 4-FC6H4CH2CO2NH, 2-ClC6H4CH(CH3)CO2NH, 2-ClC6H4CH2CH2CO2NH, 4-FC6H4CH2CO2NH, CH3(CH2)5CO2NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI




II

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intrimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

Searched by: Mary Hale 308-4258 CM-1 12D16

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, ST, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313. 19991224.

GI



AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCNH, 3-ClC6H4CH(CH3)OCNH, 4-FC6H4CH2OCNH, 2-ClC6H4CH(CH3)OCNH, 2-ClC6H4CH2CH2OCNH, 4-FC6H4CH2OCNH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2OCNH, CH3(CH2)5OCNH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prep. and biol. tested.

L3 ANSWER 21 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347156-02-9 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[1-(phenylmethyl)-4-piperidinyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C30 H33 N5 O5
 SR CA
 LC STN Files: CA, CAPLUS

GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CH₂-Ph

PAGE 2-A





PAGE 1-A

GI

REFERENCE 2: 135:76901 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.





GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


CH₂-Ph
|

PAGE 2-A



PAGE 1-A

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH2CH2OCOH, 4-2-ClC6H4CH(CH3)OCOH, (CH3)OCOH, CF3C6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclyl] and pharmaceutically acceptable salts are prep'd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed comp'd. II was prep'd. and biol. tested.



AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2CH2OCOH, 4-FC3C6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 23 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-98-0 REGISTRY

CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-[1-(phenylmethyl)-4-piperidinyl] - (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C29 H30 Cl N5 O4

SR CA

LC STN Files: CA, CAPLUS

II



GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PAGE 2-A

CH₂-Ph




PAGE 1-A

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I



AB Title comps. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 24 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-95-7 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[3-(4-methyl-1-piperazinyl)propyl] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H34 N6 O5
SR CA
LC STN Files: CA, CAPLUS



II



REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VJ, VN, YU, ZA, ZM, ZW. AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, CZ, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



GI


REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II

I




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ.
APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

19

ENCE 2: 135:76901 Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

Title comps: [1; X = N, CH, R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC3C6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.




II

AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2CH2OC(=O)NH, 4-FC6H4CH2CH2OC(=O)NH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 26 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-93-5 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[2-(4-morpholinyl)ethyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H29 N5 O6
 SR CA
 LC STN Files: CA, CAPLUS

II




GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


GI

REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prep. and biol. tested.



II




I




L3 ANSWER 27 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-92-4 REGISTRY
 CN Urea, N-[2-(diethylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H31 N5 O5
 SR CA
 LC STN Files: CA, CAPLUS


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 2 REFERENCES IN FILE CA (1967 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 REFERENCE 1: 135:92649 Preparation of quinaoline and quinoiline derivatives
 as remedies for diseases mediated by autophosphorylation of PDGF
 receptors. Sakai, Teryuki; Senga, Teruhumi; Furuta, Takayuki; Miwa,
 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890
 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,
 BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EF, ES,
 FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
 LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ,
 CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,
 ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2.
 APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;
 JP 1999-374494 19991228; JP 2000-17790 20000614.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI



I



II

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 28 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-91-3 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-(4-morpholinyl)ethyl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H27 N5 O5
SR CA
LC STN Files: CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16


GI

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.



2 REFERENCES IN FILE CA (1967 TO DATE)


2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




II






II



AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.


L3 ANSWER 29 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-89-9 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H25 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCE 1: 135:92649 Preparation of quinazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VJ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Tetsuyuki; Senga, Teruhumi; Futaba, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001/047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.




AB Title comps. [I; X = N, CH; R³, R⁴, R⁵, R⁶ independently = H, Cl, F, CH₃, CH₃O, NO₂; A = 4-CH₃C₆H₄CH₂CO₂NH, 3-ClC₆H₄CH(CH₃)OCO₂NH, 4-FC₆H₄CH₂CO₂NH, 2-ClC₆H₄CH₂CH₂CO₂NH, (CH₃CH₂)₂N(CH₂)₃NHC₆H₄YNNHC₆H₄CH₂CO₂NH, (CH₃CH₂)₂N(CH₂)₃NHC₆H₄CONHC₆H₄OH, 4-ClC₆H₄O(CH₂)₂S, 4-ClC₆H₄(CH₂)₂NH, 3-Brc₆H₄CONHC₆H₄SO₃Na, OH, OCH₂COOCH₃, OCH₂COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

Searched by: Mary Hale 308-4258 CM-1 12D16

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI



AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 30 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-83-3 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-(1-pyrroldinyl)ethyl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H27 N5 O4
SR CA
LC STN Files: CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16


GI

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI


REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, CF3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I



AB Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 31 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-69-5 REGISTRY

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[1-(phenylmethyl)-3-pyrrolidinyl] - (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C29 H31 N5 O5

SR CA

LC STN Files: CA, CAPLUS

II



GI


REFERENCE 1: 135:92649 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ph-CH₂

PAGE 2-A



PAGE 1-A


II



AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 32 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-68-4 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[1-(phenylmethyl)-3-pyrrolidinyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H28 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS

II



GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ph-CH₂

PAGE 2-A




PAGE 1-A

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I



L3	ANSWER 33 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN	347155-67-3 REGISTRY
CN	Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-(phenylmethyl)-3-pyrrolidinyl]-(9CI) (CA INDEX NAME)
FS	3D CONCORD
MF	C28 H28 Cl N5 O4
SR	CA
LC	STN Files: CA, CAPLUS

II




GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as prepd. and biol. tested.

II




I




AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 34 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-65-1 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-1-piperidinyl-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H25 N5 O4
SR CA
LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of guinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I




AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 35 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-64-0 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(hexahydro-1H-azepin-1-yl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H27 N5 O4
SR CA
LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC6NH, 3-ClC6H4CH(CH3)OC6NH, 4-FC6H4CH2OC6NH, 2-ClC6H4CH2CH2OC6NH, 4-FC6H4CH2OC6NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-Brc6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclicalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed compd. II was prepd. and b10L tested.

REFERENCE 2: 135:76901 Preparation of guinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KO, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224



AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2CH2OC(=O)NH, 4-ClC6H4CH2OC(=O)NH, 2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 36 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-63-9 REGISTRY

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-4-morpholinyl-(9CI) (CA INDEX NAME)


FS 3D CONCORD


MF C21 H23 N5 O5

SR CA

LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of guinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prep. and biol. tested.

II




I




AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.


L3 ANSWER 37 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-62-8 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-(hexahydro-1H-azepin-1-yl) - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H29 N5 O5
SR CA
LC STN Files: CA, CAPLUS

II



I





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 135:92649 Preparation of quinazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI

GI

REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as prepd. and biol. tested.



II

I

AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2CO2NH, 3-ClC6H4CH(CH3)CO2NH, 4-FC6H4CH2CO2NH, 2-ClC6H4CH(CH3)CO2NH, 2-ClC6H4CH2CH2CO2NH, 4-FC6H4CH2CO2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 38 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-61-7 REGISTRY

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C22 H25 N5 O6


SR CA


LC STN Files: CA, CAPLUS

II



I





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I




AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-NHC6H4CH2OCONH, 4-ClC6H4CH2OCONH, 2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 39 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-59-3 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-1-piperidinyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H24 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, CA, CH, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 4-ClC6H4CH2OC(=O)NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I




AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COCONH, 3-ClC6H4CH(CH3)OCOCONH, 4-FC6H4CH2COCONH, 2-ClC6H4CH(CH3)OCOCONH, 2-ClC6H4CH2CH2COCONH, 4-FC6H4CH2COCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2COCONH, CH3(CH2)5OCOCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 40 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-58-2 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-1-piperidinyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H27 N5 O5
SR CA
LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of quinaazoline and quinoaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, CH3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




I




AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2CH2OCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CFC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclialkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 41 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-57-1 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-1-piperidinyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H24 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI

19

ENCE 2: 135:76901 Preparation of quinaazoline and quinaldine derivatives
 as remedies for diseases mediated by autophosphorylation of PDGF
 receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji;
 Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;
 Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl.
 WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM,
 AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM,
 DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO,
 NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE,
 BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT,
 LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN:
 PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313
 19991224.

little compds. [I; X = N, CH, R³, R⁴, R⁵, R⁶ independently = H, Cl, F, CH₃, CH₃O, NO₂; A = 4-CH₃CH₂CH₂CO₂CH₃, 3-ClCH₂CH₂CH₂CO₂CH₃, 4-FC₆H₄CH₂CO₂CH₃, 2-ClC₆H₄CH₂CH₂CO₂CH₃, 4-FC₆H₄CH₂CO₂CH₃, CH₃(CH₂)₅CO₂CH₃, (CH₃CH₂)₂N(CH₂)₃NHCSNH, YNHCONH, 4-ClC₆H₄O(CH₂)₂S, 4-ClC₆H₄(CH₂)₂NH, 3-BrC₆H₄CONHNHCSNH, C₆H₅CO₂OH, OCH₂CO₂CH₃, OCH₂CO₂OH; Y = heterocycle, heterocycl[ylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as initial thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.




I

II

AB Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 42 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-53-7 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-(phenylmethyl)-4-piperidinyl]] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C29 H31 N5 O4
SR CA
LC STN Files: CA, CAPLUS

II



GI


REFERENCE 1: 135:92649 Preparation of quinaazoline and quinoiline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CH₂-Ph

PAGE 2-A




PAGE 1-A


GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH2OC(=O)NH, (CH3)2C(=O)NH, 4-FC6H4CH2OC(=O)NH, 4-ClC6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3)2C(=O)NH, 3-BrC6H4CH2OC(=O)NH, C6H5CO, OH, OCH2COOH, OCH2COCH3, OCH2COOCH3, Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and bio. tested.



II




I

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 43 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-49-1 REGISTRY
 CN Urea, N-[1-(cyclohexylmethyl)-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H34 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


GI

REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II




I


AB Title compds. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 44 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-48-0 REGISTRY
 CN Urea, N-[1-(cyclohexylmethyl)-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H35 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II



I




GI


REFERENCE 1: 135:92649 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

GI


REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prep. and biol. tested.



LC STN Files: CA, CAPLUS
 SR CA
 MF C32 H36 N6 O6
 FS 3D CONCORD
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[1-[[4-
 RN 347155-46-8 REGISTRY
 L3 ANSWER 45 OF 179 REGISTRY COPYRIGHT 2002 ACS
 Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2COONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2COONH, 4-CF3C6H4CH2COONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kitin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BY, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486.19991224;


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




PAGE 2-A



PAGE 1-A



I



II


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2CH2OC(=O)NH, 4-CF3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CFC6H4CH2OC(=O)NH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 46 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-45-7 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-[(4-(1,1-dimethyl)ethyl)phenyl]methyl]-3-pyrrolidinyl]-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C32 H37 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II



I




REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kitin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




PAGE 2-A



PAGE 1-A

19

title compds. [1; X = N, CH, R³, R⁴, R⁵, R⁶ independently = H, Cl, F, CH₃,
 CH₃O, NO₂; A = 4-CH₃OC₆H₄CH₂OC₆H₄, 3-ClC₆H₄CH₂OC₆H₄, 4-FC₆H₄CH₂OC₆H₄,
 2-ClC₆H₄CH₂CH₂OC₆H₄, 4-
 CF₃OC₆H₄CH₂OC₆H₄, CH₃(CH₂)₅OC₆H₄, (CH₃CH₂)₂N(CH₂)₃NHCSNH, YNHCONH,
 4-ClC₆H₄O(CH₂)₂S, 4-ClC₆H₄(CH₂)₂NH, 3-BrC₆H₄CONHCSNH, C₆H₅COO, OH,
 OCH₂COOCH₃, OCH₂COOH; Y = heterocycle, heterocyclalkyl] and
 pharmaceutically acceptable salts are prep'd. as remedies for diseases
 mediated by autophosphorylation of PDGF receptors, particularly useful as
 initial thickening inhibitors. Thus, the title claimed compd. II was
 prep'd. and bptl. tested.




II

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 47 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-43-5 REGISTRY
CN Urea, N-[1-[(2-chlorophenyl)methyl]-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H27 Cl N6 O6
SR CA
LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


GI

REFERENCE 2: 135:76901 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II



I

AB Title comps. [1: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2CO2NH, 3-ClC6H4CH2CO2NH, 4-FC6H4CH2CO2NH, 2-ClC6H4CH2CO2NH, 2-ClC6H4CH2CH2CO2NH, 4-FC6H4CH2CH2CO2NH, 4-ClC6H4CH2CO2NH, CH3(CH2)5CO2NH, (CH3CH2)2N(CH2)3NHCSNH, C6H5CO2OH, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO2OH, OCH2CO2CH3, OCH2CO2H; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 48 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-42-4 REGISTRY

CN Urea, N-[1-[(2-chlorophenyl)methyl]-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl] - (9CI) (CA INDEX NAME)


FS 3D CONCORD



MF C28 H28 Cl N5 O4

SR CA

LC STN Files: CA, CAPLUS

II





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoiline derivatives as remedies for diseases mediated by autophosphorylation of PDGF

receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

Searched by: Mary Hale 308-4258 CM-1 12D16


GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




Absolute stereochemistry.


LC STN Files: CA, CAPLUS
 SR CA
 MF C28 H28 N6 O6
 FS STEREOSEARCH
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[(3S)-1-
 RN 347155-40-2 REGISTRY
 L3 ANSWER 49 OF 179 REGISTRY COPYRIGHT 2002 ACS


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2CO2NH, 3-ClC6H4CH2CO2NH, 4-FC6H4CH2CO2NH, 2-ClC6H4CH2CO2NH, 2-ClC6H4CH2CH2CO2NH, 4-FC6H4CH2CO2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. It was prepd. and biol. tested.

II



I






2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1 : 135:92649 Preparation of quinazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BG, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI




AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCNH, 3-ClC6H4CH(CH3)OCNH, 4-FC6H4CH2OCNH, 2-ClC6H4CH(CH3)OCNH, 2-ClC6H4CH2CH2OCNH, 4-FC6H4CH2OCNH, CH3C6H4CH2OCNH, CH3(CH2)5OCNH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2OCNH, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 50 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-39-9 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl] - (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H28 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


GI

GI


REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5CO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5CO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intrimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I






II

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 51 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-38-8 REGISTRY
 CN Urea, N-(2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl)-N'-[(3S)-1-(phenylmethyl)-3-pyrrolidyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H28 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS
 Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Searched by: Mary Hale 308-4258 CM-1 12D16


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors: Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI



I




II

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2CO2NH, 3-ClC6H4CH(CH3)OCO2NH, 4-FC6H4CH2CO2NH, 2-ClC6H4CH(CH3)OCO2NH, 2-ClC6H4CH2CH2CO2NH, 4-FC6H4CH2CO2NH, CH3(CH2)5OCO2NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, CF3C6H4CH2CO2NH, 4-ClC6H4(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as prepd. and biol. tested.

Searched by: Mary Hale 308-4258 CM-1 12D16

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CH, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI




AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, CH3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 52 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 347155-37-7 REGISTRY
CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H28 Cl N5 O4
SR CA
LC STN Files: CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors.


Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI


GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakkō Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COONH, 3-ClC6H4CH(CH3)OCOONH, 4-FC6H4CH2COONH, 2-ClC6H4CH(CH3)OCOONH, 2-ClC6H4CH2CH2COONH, 4-CF3C6H4CH2COONH, CH3(CH2)5OCOONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



II




I


LC STN Files: CA, CAPLUS
 SR CA
 MF C29 H30 Cl N5 O4
 FS 3D CONCORD
 CN methylphenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
 RN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-[(2-
 347155-35-5 REGISTRY
 L3 ANSWER 53 OF 179 REGISTRY COPYRIGHT 2002 ACS

AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclialkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II



I




GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PAGE 2-A




PAGE 1-A




19

REFERENCE 2: 135:76901 Preparation of guinazoline and guinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, NA, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclyl] and pharmaceutically acceptable salts are prep'd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed comp'd. II was prep'd. and bptl. tested.




I



LC STN Files: CA, CAPLUS
 SR CA
 MF C30 H33 N5 O5
 FS 3D CONCORD
 CN methylphenyl(methyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
 RN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[1-[(2-347155-33-3 REGISTRY
 L3 ANSWER 54 OF 179 REGISTRY COPYRIGHT 2002 ACS

AB Title compds. [I; X = N, CH, R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

II




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




PAGE 2-A




PAGE 1-A

II



AB Title compds. [I; X = N, CH, R³, R⁴, R⁵, R⁶ independently = H, Cl, F, CH₃, CH₃O, NO₂; A = 4-CH₃CH₆CH₂OCNH, 3-ClCH₄CH(CH₃)OCNH, 4-FC₆H₄CH₂OCNH, 2-ClCH₆4CH(CH₃)OCNH, 2-ClCH₆4CH₂CH₂OCNH, 4-FC₃CH₆4CH₂OCNH, CH₃(CH₂)₅OCNH, (CH₃CH₂)₂N(CH₂)₃NHCSNH, YNHCONH, 4-ClCH₆4O(CH₂)₂S, 4-ClCH₆4(CH₂)₂NH, 3-BrC₆H₄CONHCSNH, C₆H₅COO, OH, OCH₂COOCH₃, OCH₂COOH; Y = heterocycle, heterocyclialkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

19

REFERENCE 2: 135:76901 Preparation of guinazoline and guinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Little comps. [I; X = N, CH, R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, (CH3)OCOH, 4-ClC6H4O, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intraluminal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



AB Title compds. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 56 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-31-1 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-[(2-methylphenyl)methyl]-3-pyrrolidinyl]]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C29 H31 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II




GI


REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


19

REFERENCE 2: 135:76901 Preparation of guinazoline and guinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AT, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TW, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, TW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH2CH2OCOH, 4-CF3C6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclicalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as internal thickening inhibitors. Thus, the title claimed compd. II was prepd. and bptl. tested.




I




AB Title compds. [I; X = N, CH, R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 57 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-30-0 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2,2,6,6-tetramethyl-4-piperidyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H33 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

II



I




GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




GI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakashita, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



Absolute stereochemistry.

L3 ANSWER 58 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 347155-29-7 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H29 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS

AB Title comps. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COONH, 3-ClC6H4CH(CH3)COONH, 4-FC6H4CH2COONH, 2-ClC6H4CH(CH3)COONH, 2-ClC6H4CH2CH2COONH, 4-FC6H4CH2COONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCOONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.





2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaldine derivatives

as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI




AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COONH, 3-ClC6H4CH2COONH, 4-FC6H4CH2COONH, 2-ClC6H4CH2COONH, 2-ClC6H4CH2CH2COONH, 4-FC6H4CH2COONH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CF3C6H4CH2COONH, CH3(CH2)5COONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prep. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prep. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinaazoline and quinaldine derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI



AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOH, 3-ClC6H4CH(CH3)OCOH, 4-FC6H4CH2OCOH, 2-ClC6H4CH(CH3)OCOH, 2-ClC6H4CH2CH2OCOH, 4-FC6H4CH2OCOH, CH3(CH2)5OCOH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOH, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 59 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 347155-28-6 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H29 N5 O4
SR CA
LC STN Files: CA, CAPLUS
Absolute stereochemistry.


Searched by: Mary Hale 308-4258 CM-1 12D16

GI

REFERENCE 1: 135:92649 Preparation of quinoxaline and quinoxaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



GI

REFERENCE 2: 135:76901 Preparation of quinaazoline and quinoaline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakatsuki, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LV, LU, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KY, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.


AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OC(=O)NH, 3-ClC6H4CH(CH3)OC(=O)NH, 4-FC6H4CH2OC(=O)NH, 2-ClC6H4CH(CH3)OC(=O)NH, 2-ClC6H4CH2CH2OC(=O)NH, 4-FC3C6H4CH2OC(=O)NH, CH3(CH2)5OC(=O)NH, (CH3CH2)2N(CH2)3NHCSNH, YNHCSNH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intral thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.



AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2CH2OCONH, 4-CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclialkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 60 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 346467-61-6 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-(1-piperidinyl)ethyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H28 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS

II




GI

REFERENCE 1: 135:92649 Preparation of quinaazoline and quinaoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.


2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A


19


ENCE 2: 135;76901 Preparation of quinaazoline and quinaline derivatives
 as remedies for diseases mediated by autophosphorylation of PDGF
 receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;
 Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;
 Nakaniishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl.
 WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM,
 AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM,
 DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KR, KZ, LC, LK, LR, LS, LT, LV, LU, MD, MG, MK, MN, MW, MX, NO,
 NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE,
 BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT,
 LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN:
 PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313
 19991224.

Title comps. [1; X = N, CH; R³, R⁴, R⁵, R⁶ independently = H, Cl, F, CH₃, CH₃O, NO₂; A = 4-CH₃CH₆CH₂CO₂CH₃, 3-ClCH₆CH₄CH₂CO₂CH₃, 4-FC₆H₄CH₂CO₂CH₃, 2-ClC₆H₄CH₂CH₂CO₂CH₃, 4-FC₃CH₆H₄CH₂CO₂CH₃, CH₃(CH₂)₅CO₂CH₃, (CH₃CH₂)₂N(CH₂)₃NHCSNH, YNHCONH, 4-ClC₆H₄O(CH₂)₂S, 4-ClC₆H₄(CH₂)₂NH, 3-BrC₆H₄CONHNHCSNH, C₆H₅COO, OH, OCH₂COOCH₃, OCH₂COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as initial thickening inhibitors. Thus, the title claimed compd. II was prepd. and bptl. tested.




I





L3 ANSWER 61 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 346467-60-5 REGISTRY
 CN Urea, N-[2-(diethylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H28 N6 O6
 SR CA
 LC STN Files: CA, CAPLUS

AB Title comps. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.




II


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinaldine derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Sakai, Tetsuyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atsushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; JP 1999-374494 19991228; JP 2000-177790 20000614.

GI



I




II

AB Title comps. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors, particularly useful as intraluminal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshitsa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakamishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 19991224.

GI




AB Title compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-ClC6H4CH(CH3)OCONH, 2-ClC6H4CH2CH2OCONH, 4-FC6H4CH2OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, CF3C6H4CH2OCONH, CH3(CH2)5OCONH, (CH3CH2)2N(CH2)3NHCSNH, YNHCONH, 4-ClC6H4O(CH2)2S, 4-ClC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclalkyl] and pharmaceutically acceptable salts are prepd. as remedies for diseases mediated by autophosphorylation of PDGF receptors. Thus, the title claimed compd. II was prepd. and biol. tested.

L3 ANSWER 62 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 286372-08-5 REGISTRY
CN Urea, N-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 Cl N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
Searched by: Mary Hale 308-4258 CM-1 12D16

AB Little comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H,

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPIUS (1967 TO DATE)
 REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,
 anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines
 and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin
 Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 200043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, GR,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.




alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 63 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286372-07-4 REGISTRY
CN Urea, N'-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C21 H22 Br Cl N4 O4

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 64 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286372-06-3 REGISTRY
 CN Urea, N'-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C18 H17 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, GR,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AZ, BY,
 CG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 65 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-99-1 REGISTRY
 CN Urea, N-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinoxalinyloxy]-2-methoxyphenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H23 Br F2 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

F

PAGE 2-A




PAGE 1-A



I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 66 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-98-0 REGISTRY
 CN Urea, N-(2,4-difluorophenyl)-N'-[4-[(7-hydroxy-6-methoxy-4-guinazo[1,2-b]pyridin-2-yl)oxy]-2-methoxyphenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H18 F2 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PAGE 1-A


F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title compds. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 67 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-97-9 REGISTRY


CN Urea, N-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-

Searched by: Mary Hale 308-4258 CM-1 12D16

methoxyphenyl]-N'-propyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C23 H27 Br N4 O5

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. confg. the same are prep'd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prep'd. and tested.

L3 ANSWER 68 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-96-8 REGISTRY


CN Urea, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-propyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H22 N4 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 69 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-93-5 REGISTRY


CN Urea, N-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H20 Br Cl F2 N4 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER



I

GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IL, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PAGE 2-A

F




PAGE 1-A



PAGE 1-A

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 70 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 286371-92-4 REGISTRY
CN Urea, N-[4-[[7-(2-bromoethoxy)-6-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H18 Br Cl F2 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



I


F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 71 OF 179 REGISTRY COPYRIGHT 2002 ACS


RN 286371-91-3 REGISTRY

CN Urea, N-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyloxy]phenyl]-N'-

Searched by: Mary Hale 308-4258 CM-1 12D16

(2,4-difluorophenyl) - (9CI) (CA INDEX NAME)
 3D CONCORD
 MF C22 H15 Cl F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A




PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prep. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prep. and tested.

L3 ANSWER 72 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-84-4 REGISTRY
 CN Urea, N-[2-chloro-4-[(7-methoxy-6-propoxy-4-quinazolinyl)oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H25 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. confg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 73 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-83-3 REGISTRY
 CN Urea, N-[4-[[6-(3-bromopropoxy)-7-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H24 Br Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I


AB

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

Searched by: Mary Hale 308-4258 CM-1 12D16

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 74 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-82-2 REGISTRY
 CN Urea, N-[2-chloro-4-[(6-hydroxy-7-methoxy-4-quinazolinyl)oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H19 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 75 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-81-1 REGISTRY
 CN Urea, N-[4-[[6-(2-bromoethoxy)-7-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H22 Br Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
 CG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 76 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-80-0 REGISTRY
 CN Urea, N-[4-[[7-(4-bromobutoxy)-6-methoxy-4-quinazolinyloxy]-2-chlorophenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H26 Br Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or


aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 77 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-79-7 REGISTRY
CN Urea, N'-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C20 H21 Cl N4 O4
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 78 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-78-6 REGISTRY
 CN Urea, N-[4-[[7-[(5-bromopentyl)oxy]-6-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H28 Br Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. confg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 79 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-77-5 REGISTRY
 CN Urea, N-[4-[[7-(2-bromoethoxy)-6-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H22 Br Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I


AB

Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 80 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-76-4 REGISTRY
CN Urea, N-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-chlorophenyl]-N'-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H24 Br Cl N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, DE, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI

Searched by: Mary Hale 308-4258 CM-1 12D16



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 81 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-68-4 REGISTRY
 CN Urea, N-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H19 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16


Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 82 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-67-3 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H25 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, MC, ML, MR, NE, NL, PT, SE, SN, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or


aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 83 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-42-4 REGISTRY
CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C26 H32 Cl N5 O4
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 84 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-41-3 REGISTRY
CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C25 H30 Cl N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16


Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 85 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-40-2 REGISTRY
 CN Urea, N'-[2-chloro-4-[[[7-(3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]oxy]phenyl]-N,N-dimethyl-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H30 Cl N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all




GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, TW, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 86 OF 179 REGISTRY COPYRIGHT 2002 ACS

LN 286371-39-9 REGISTRY
CN Urea, N'-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C26 H33 Cl N6 O4

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 87 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-38-8 REGISTRY
 CN Acetic acid, [[4-[3-chloro-4-[[[(dimethylamino)carbonyl]amino]phenoxy]-6-methoxy-7-quinazolinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H21 Cl N4 O6
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines


and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkyldithio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 88 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-37-7 REGISTRY
 CN Urea, N'-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H22 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, MC, ML, MR, NE, NL, PT, SE, SN, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 89 OF 179 REGISTRY COPYRIGHT 2002 ACS

LC 286371-36-6 REGISTRY
 RN Urea, N'-[2-chloro-4-[[6-methoxy-7-[4-(4-morpholinyl)butoxy]-4-quinazolinyl]oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H32 Cl N5 O5
 SR CA
 LC STN files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DE, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 90 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-35-5 REGISTRY
 CN Urea, N'-[2-chloro-4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H28 Cl N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, GR,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
 CG, CZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 91 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-29-7 REGISTRY
 CN Urea, N-(2,4-difluorophenyl)-N'-[2-methoxy-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]oxy]phenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C30 H31 F2 N5 O6
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16

GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

F

PAGE 2-A



PAGE 1-A



I


AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 92 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-28-6 REGISTRY
CN Urea, N-[2-methoxy-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-

quinoxalinyloxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C27 H35 N5 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinoxalines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


L3 ANSWER 93 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-22-0 REGISTRY
 CN Urea, N-[2-chloro-4-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H28 Cl F2 N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

GI


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, DE, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




PAGE 2-A



PAGE 1-A

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 94 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-21-9 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C30 H31 Cl F2 N6 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




GI


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DE, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A



PAGE 1-A



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 95 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286371-20-8 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C29 H28 Cl F2 N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

F

PAGE 2-A



PAGE 1-A



PAGE 1-A

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 96 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-19-5 REGISTRY


CN Urea, N-[2-chloro-4-[[6-methoxy-7-(2-(4-morpholinyl)ethoxy]-4-quinazolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H26 Cl F2 N5 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER



I


1

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


L3 ANSWER 97 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286371-18-4 REGISTRY

CN Urea, N-[2-chloro-4-[[6-methoxy-7-(4-pyridinyl)methoxy]-4-

quinazolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
3D CONCORD
MF C28 H20 Cl F2 N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A




PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

Searched by: Mary Hale 308-4258 CM-1 12D16




ANSWER 98 OF 179 REGISTRY COPYRIGHT.2002 ACS
286370-97-6 REGISTRY
Urea, N-[2-chloro-4-[[6-[3-[(2-hydroxyethyl)methylamino]propoxy]-7-methoxy-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)

COc1cc2c(cc1OC)ncnc2Oc3ccc(NC(=O)Nc4ccc(Cl)cc4)cc3

Searched by: Mary Hale 308-4258 CM-1 12D16

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 99 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-96-5 REGISTRY
 CN Urea, N-[2-chloro-4-[[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H32 Cl N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title compds. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

I




GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 100 OF 179 REGISTRY. COPYRIGHT 2002 ACS

RN 286370-95-4 REGISTRY
CN Urea, N-[2-chloro-4-[[7-methoxy-6-(2-pyridinylmethoxy)-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H24 Cl N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 101 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-94-3 REGISTRY
 CN Urea, N-[2-chloro-4-[[7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H35 Cl N6 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 CG, CZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. confg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 102 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-93-2 REGISTRY
 CN Urea, N-[2-chloro-4-[[7-methoxy-6-(2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H33 Cl N6 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

little compds. I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxyl, etc.; R4 represents H; R5-8 represent each H, H, halogeno, alkyl, alkoxyl, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

I




19

ENCE I : I33:I35235 Preparation and anti-tumor, anti-atherosclerosis,
 anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines
 Beer Kabushiki Kaisha, Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kiritn
 PCT Int. Appl. WO 200043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MT, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP25 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPTUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 103 OF 179 REGISTRY COPYRIGHT 2002 ACS

LC 286370-91-0 REGISTRY
CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H34 Cl N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DE, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese): CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 104 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-89-6 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-[(1-methyl-1H-tetrazol-5-yl)thio]propoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H27 Cl N8 O4 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 105 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-88-5 REGISTRY
 CN Urea, N-(2-chloro-4-[[6-methoxy-7-[3-(4-pyridinylthio)propoxy]-4-quinazolinyl]oxy]phenyl)-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H28 Cl N5 O4 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

I




GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 106 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-87-4 REGISTRY
 CN Carbamate acid, diethyl-, 3-[[4-[3-chloro-4-[[[(diethylamino)carbonyl]amino]phenoxy]-6-methoxy-7-quinazolinyl]oxy]propyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H36 Cl N5 O6
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

G1

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



L3 ANSWER 107 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 286370-86-3 REGISTRY
CN Urea, N'-[2-chloro-4-[[6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazolinyl]oxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 Cl N7 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER


AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



I

Searched by: Mary Hale 308-4258 CM-1 12D16

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxyl, etc.; R4 represents H; R5-8 represent each H, H, halogeno, alkyl, alkoxy, alkyldithio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.




Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, DE, KG, KZ, MD, RU, TJ, TM, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT






I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 110 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-83-0 REGISTRY
 CN Urea, N-[2-chloro-4-[[[6-methoxy-7-(2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H33 Cl N6 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 111 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-82-9 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-[4-(4-morpholinyl)butoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H34 Cl N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

I




GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, CG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 112 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286370-81-8 REGISTRY
CN Urea, N'-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]oxy]phenyl]-N,N-dieethyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C26 H26 Cl N5 O4
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DE, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 113 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-80-7 REGISTRY
 CN Urea, N-[2-chloro-4-[[[6-methoxy-7-[[[5-(1H-1,2,3-triazol-1-yl)pentyl]oxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H30 Cl N7 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 114 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-79-4 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-[[5-(4-morpholinyl)pentyl]oxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H36 Cl N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkenyl, alkenyl, alkenyl, alkenyl, alkenyl or

I




GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 115 OF 179 REGISTRY COPYRIGHT 2002 ACS

LC 286370-78-3 REGISTRY
CN Urea, N-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H24 Cl N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, DE, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 116 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-77-2 REGISTRY
 CN Urea, N-[2-chloro-4-[[7-(2-hydroxyethoxy)-6-methoxy-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 Cl N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin


Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 117 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-76-1 REGISTRY
 CN Urea, N-[2-chloro-4-[[7-(3-hydroxypropoxy)-6-methoxy-4-guinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H25 Cl N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, MC, ML, MR, NE, NL, PT, SE, SN, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 118 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286370-75-0 REGISTRY
CN Urea, N-[2-chloro-4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H30 Cl N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, DE, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16

I



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 119 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-74-9 REGISTRY
 CN Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H32 Cl N5 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 120 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-73-8 REGISTRY
 CN Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H19 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

ANSWER 121 OF 179 REGISTRY COPYRIGHT 2002 ACS

LC 286370-72-7 REGISTRY
 RN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-methyl-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C18 H17 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 122 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-71-6 REGISTRY
 CN Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

19



T

AB

LC
SR
MF
FS
CN
RN
L3

See


Searched by: Mary Hale 308-4258 CM-1 12D16

19

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT
 1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,
 anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines
 and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin
 Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907


1

PAGE 2-A




PAGE 1-A

I



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 124 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-69-2 REGISTRY
 CN Urea, N-butyl-N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H25 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16


Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 125 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-68-1 REGISTRY
 CN Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H27 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 126 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-67-0 REGISTRY
 CN Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-ethyl-N-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H25 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 127 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-66-9 REGISTRY
 CN Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin


Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AT, AM, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 CG, KZ, MD, RU, TJ, TM; AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.



AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. confg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 128 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-65-8 REGISTRY
 CN Acetamide, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-
 FS 3D CONCORD
 MF C22 H23 Cl N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

. 1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB

Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or


aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 129 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286370-64-7 REGISTRY
CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-(methoxymethyl)-N'-propyl- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C22 H25 Cl N4 O5
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 130 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-63-6 REGISTRY
 CN Urea, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 N5 O6
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 131 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-62-5 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-propyl-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C20 H21 N5 O6
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl]], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 132 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-61-4 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-N'-(2-methoxyphenyl) - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H24 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI

AB Title comps. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



L3 ANSWER 133 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-60-3 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-N'-(4-fluorophenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H21 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

GI


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, ST, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

F

PAGE 2-A



PAGE 1-A




I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 134 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-58-9 REGISTRY
 CN Urea, N-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H20 F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A




F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, BU, MC, ML, MR, NE, NL, PT, SE, SN, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3

ANSWER 135 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN


286370-56-7 REGISTRY

CN

Urea, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-

Searched by: Mary Hale 308-4258 CM-1 12D16

I




GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinoxalines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



FS 3D CONCORD
MF C22 H26 N4 O4
SR CA
LC STN Files: CA, CAPUS, TOXCENTER

AB Title compds. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


L3 ANSWER 136 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-55-6 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-N'-propyl-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H24 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



L3 ANSWER 137 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-54-5 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-N'-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H24 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



AB

Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3

ANSWER 138 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN

286370-53-4 REGISTRY

CN

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-N'-(4-fluorophenyl)-(9CI) (CA INDEX NAME)

FS

3D CONCORD

MF

C24 H21 F N4 O4

SR

CA

STN Files: CA, CAPLUS, TOXCENTER

LC

GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

F

PAGE 2-A



PAGE 1-A




I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 139 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-52-3 REGISTRY
 CN Urea, N-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H20 F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A




F
|

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


L3 ANSWER 140 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286370-50-1 REGISTRY

CN Urea, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-

Searched by: Mary Hale 308-4258 CM-1 12D16

FS 3D CONCORD
MF C22 H26 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 141 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-48-7 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H24 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, ST, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 142 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-47-6 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-(2-methoxyphenyl) - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H21 F N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI

I



AB

Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkanyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. confg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3

ANSWER 143 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN

286370-46-5 REGISTRY

CN

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-(2-methylphenyl)-(9CI) (CA INDEX NAME)

FS

3D CONCORD

MF


C24 H21 F N4 O4

SR

CA

STN Files: CA, CAPLUS, TOXCENTER

LC




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

Searched by: Mary Hale 308-4258 CM-1 12D16

optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 144 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-45-4 REGISTRY
 CN Urea, N-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H17 F3 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PAGE 1-A

PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Searched by: Mary Hale 308-4258 CM-1 12D16

anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


L3 ANSWER 145 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-44-3 REGISTRY
 CN Urea, N-[(2,4-difluorophenyl)methyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H19 F3 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

GI


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




L3 ANSWER 146 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 286370-43-2 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-2-propynyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H17 F N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



I


and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



I

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 147 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-42-1 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-2-propenyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C20 H19 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 148 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-41-0 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-(1-methylpropyl) - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16

I



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 149 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-40-9 REGISTRY
 CN Urea, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinés. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16


Searched by: Mary Hale 308-4258 CM-1 12D16

L3	ANSWER 150 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN	286370-39-6 REGISTRY
CN	Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-propyl-
FS	3D CONCORD (9CI) (CA INDEX NAME)
MF	C20 H21 F N4 O4
SR	CA
LC	STN Files: CA, CAPLUS, TOXCENTER

AB little compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. confg. the same are prep'd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prep'd. and tested.



Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 151 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-38-5 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(5-chloro-2-pyridinyl) - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H17 Cl2 N5 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A



PAGE 2-A

Cl
|

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,

Searched by: Mary Hale 308-4258 CM-1 12D16

BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 152 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 286370-37-4 REGISTRY
CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H21 Cl N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H,

Searched by: Mary Hale 308-4258 CM-1 12D16

optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

LC
SR
MF
FS
CN
RN
L3
ANSWER 153 OF 179 REGISTRY COPYRIGHT 2002 ACS
286370-35-2 REGISTRY
Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-(9CI) (CA INDEX NAME)
3D CONCORD
C23 H18 Cl F N4 O4
CA
STN Files: CA, CAPLUS, TOXCENTER



PAGE 1-A

PAGE 2-A

F

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, Searched by: Mary Hale 308-4258 CM-1 12D16

anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

I



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 154 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-34-1 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H20 Cl N5 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER


GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




PAGE 2-A



PAGE 1-A

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 155 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-33-0 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[(2,4-difluorophenyl)methyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H19 Cl F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




I

GI


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasumari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




PAGE 2-A




PAGE 1-A

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerotic, anti-psoriasis, anti-diabetes, anti-arthritis activities of gubunolines

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. confg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



I

19




I

AB

LC
SR
MF
FS
CN
RN
L3

Seas




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB

Title compds. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 158 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-30-7 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(1-methylpropyl) - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H23 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AT, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 159 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-29-4 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-pentyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H25 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
19990521; JP 1999-253624 19990907.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI


I



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 161 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-27-2 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-ethyl-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H19 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



LC STN Files: CA, CAPLUS, TOXCENTER
 SR CA
 MF C24 H22 N4 O4
 FS 3D CONCORD
 (9CI) (CA INDEX NAME)
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-methylphenyl)-
 RN 286370-26-1 REGISTRY
 L3 ANSWER 162 OF 179 REGISTRY COPYRIGHT 2002 ACS


AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



Searched by: Mary Hale 308-4258 CM-1 12D16

LC	STN files: CA, CAPLUS, TOXCENTER
SR	CA
MF	C23 H19 F N4 O4
FS	3D CONCORD
	(9CI) (CA INDEX NAME)
CN	Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-
RN	286370-25-0 REGISTRY
I3	ANSWER 163 OF 179 REGISTRY COPYRIGHT 2002 ACS

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,
anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinalines
Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 200043366 A1 20000727,
Fujiwara, Yasunari, Isoe, Toshiyuki (Kirin
208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VN, ZA, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```


GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

F

PAGE 2-A




PAGE 1-A



PAGE 1-A

L3 ANSWER 164 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-24-9 REGISTRY
 CN Urea, N-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl] - (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H18 F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.



I


F
|

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I

AB

Title compds. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3

ANSWER 165 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN

286370-23-8 REGISTRY

CN

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-


Searched by: Mary Hale 308-4258 CM-1 12D16

CA

Searched by: Mary Hale 308-4258 CM-1 12D16

TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


L3 ANSWER 166 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-22-7 REGISTRY
 CN Urea, N-[(2,4-difluorophenyl)methyl]-N'-[(4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H20 F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

GI


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, DE, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PAGE 2-A




PAGE 1-A



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. congt. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 167 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-21-6 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-2-propynyl- (9CI)
 FS 3D CONCORD
 MF C20 H18 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

GI
and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, BU, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 168 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 286370-20-5 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-2-propenyl- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C20 H20 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI



I


AB Title comps. [I: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

Searched by: Mary Hale 308-4258 CM-1 12D16

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 169 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286370-19-2 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(1-methylpropyl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H24 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

G1


Searched by: Mary Hale 308-4258 CM-1 12D16



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 170 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-18-1 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-pentyl- (9CI)
 FS 3D CONCORD
 MF C22 H26 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 171 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-17-0 REGISTRY
 CN Urea, N-[(6,7-dimethoxy-4-guinaazolinyloxy]phenyl]-N'-propyl- (9CI)
 FS 3D CONCORD
 MF C20 H22 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.

GI




I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

aralkyl]], pharmaceutically acceptable salts and solvates, and medicinal compds. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 172 OF 179 REGISTRY COPYRIGHT 2002 ACS

RN 286370-16-9 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H20 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 173 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-15-8 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C20 H21 Cl N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

Searched by: Mary Hale 308-4258 CM-1 12D16

Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727,
 208 pp. DESIGNATED STATES: W: AE, AT, AM, AU, AZ, BA, BB, BG, BR,
 BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 CG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
 DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
 TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.
 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
 19990521; JP 1999-253624 19990907.

GI



I

AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 174 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 286370-14-7 REGISTRY
 CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2,4-difluorophenyl)-(9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H17 Cl F2 N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16

GI

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolinones. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

PAGE 2-A

F




PAGE 1-A

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Ise, Toshiyuki (Kirin

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




L3 ANSWER 175 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 190728-01-9 REGISTRY
CN Urea, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl] - (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H24 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

AB Title comps. [1: X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


I



AB title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkyldithio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.




Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000/43366 A1 20000727,
208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION: WO 2000-JP25 20000120.
PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493
19990521; JP 1999-253624 19990907.



L3 ANSWER 176 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 190728-00-8 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-fluorophenyl)-
 FS 3D CONCORD
 MF C23 H19 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

AB The title compds. I [R1 and R2 represent each H or Cl-4 alkyl, or R1 and R2 together form Cl to C3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl] are prepd. I inhibit platelet-derived growth factor receptor autophosphorylation and are useful in the treatment of cancer, arthritis, etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for 9 days) increased the survival of mice with transplanted leukemic P388 cells by 130%.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:34137 Preparation of quinoline and quinazoline derivatives
inhibiting platelet-derived growth factor receptor autophosphorylation.
Kato, Kazuo; Ohyama, Shinichi; Shimizu, Nishiyuki; Nishiyuki, Tsuyoshi;
Kato, Shinichi; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer
Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu,
Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichi). PCT Int. Appl. WO
9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU,
IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA,
UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ,
CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML,
MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION:
WO 1996-JP3229 19961105. PRIORITY: JP 1995-313555 19951107; JP 1996-62121
19960223.


GI



AB The title comps. I [R1 and R2 represent each H or C1-4 alkyl, or R1 and R2 together form C1 to C3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl] are prep'd. I inhibit platelet-derived growth factor receptor autophosphorylation and are useful in the treatment of cancer, arthritis, etc. The title comp'd. II (prep'n. given) (at 100 mg/kg i.p. once daily for 9 days) increased the survival of mice with transplanted leukemic P388 cells by 130%.

L3 ANSWER 177 OF 179 REGISTRY COPYRIGHT 2002 ACS
RN 190727-99-2 REGISTRY
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H22 N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 127:34137 Preparation of quinoline and quinazoline derivatives
inhibiting platelet-derived growth factor receptor autophosphorylation.
Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi;
Kato, Shinichi; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer
Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu,
Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichi). PCT Int. Appl. WO
9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU,
IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, UA,
UG, US, VZ, VN, AM, AZ, BY, BG, GR, IE, IT, LU, MC, ML,
MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXDZ. APPLICATION:
WO 1996-JP3229 19961105. PRIORITY: JP 1995-313555 19951107; JP 1996-62121
19960223.

GI




L3 ANSWER 178 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 190727-98-1 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-methoxyphenyl)-
 FS 3D CONCORD
 MF C24 H22 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

AB The title compds. I [R1 and R2 represent each H or Cl-4 alkyl, or R1 and R2 together form Cl to C3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl] are prepd. I inhibit platelet-derived growth factor receptor autophosphorylation and are useful in the treatment of cancer, arthritis, etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for 9 days) increased the survival of mice with transplanted leukemic P388 cells by 130%.




2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPTUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 A1 20000727, 208 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, ZA, ZM, AM, AZ, BY, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 19990521; JP 1999-253624 19990907.



AB Title comps. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkyldithio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal comps. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.


REFERENCE 2: 127:34137 Preparation of quinaline and quinalazine derivatives
inhibiting platelet-derived growth factor receptor autophosphorylation.
Kato, Shinichiro; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi;
Kato, Shinichiro; Murooka, Hideo; Kobayashi, Yoshiko; et al. (Kirin Beer
Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu,
Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichiro). PCT Int. Appl. WO
9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU,
IT, IS, JP, KE, KG, KR, KZ, LC, LR, LS, LT, LU, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA,
UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ,
CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML,
MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION
WO 1996-JP3229 19961105. PRIORITY: JP 1995-313555 19951107; JP 1996-62121
19960223.



AB The title compds. I [R1 and R2 represent each H or C1-4 alkyl, or R1 and R2 together form C1 to C3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl] are prepd. I inhibit platelet-derived growth factor receptor autophosphorylation and are useful in the treatment of cancer, arthritis, etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for 9 days) increased the survival of mice with transplanted leukemic P388 cells by 130%.

L3 ANSWER 179 OF 179 REGISTRY COPYRIGHT 2002 ACS
 RN 190727-97-0 REGISTRY
 CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(4-methoxyphenyl)-
 FS 3D CONCORD
 MF C24 H22 N4 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

OMe



PAGE 1-A

PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:34137 Preparation of quinoline and quinazoline derivatives
inhibiting platelet-derived growth factor receptor autophosphorylation.
Kubo, Kazuo; Ohshima, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi;
Kato, Shinichi; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer
Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohshima, Shinichi; Shimizu,
Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichi). PCT Int. Appl. WO
9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: AT, AM, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU,
IL, IS, JP, KE, KR, KZ, LC, LR, LS, LT, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA,
UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM: RW: AT, BE, BF, BJ,
CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML,
MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION:
WO 1996-JP3229 19961105. PRIORITY: JP 1995-313555 19951107; JP 1996-62121
19960223.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16

AB The title comps. I [R1 and R2 represent each H or Cl-4 alkyl, or R1 and R2 together form Cl to C3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl] are prepd. I inhibit platelet-derived growth factor receptor autophosphorylation and are useful in the treatment of cancer, arthritis, etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for 9 days) increased the survival of mice with transplanted leukemic P388 cells by 130%.



=> fil caol's 13 COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE
FILE 'CAOLD' ENTERED AT 08:51:50 ON 09 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)
This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.
This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.
L4 0 L3
=> del his y
COST IN U.S. DOLLARS
SINCE FILE ENTRY
TOTAL SESSION

Searched by: Mary Hale 308-4258 CM-1 12D16